CTEPH (chronic thromboembolic pulmonary hypertension)
Conditions
Interventions
Initiation of once-daily Edoxaban(60mg) during 6 months after 2 days discontinuation of warfarin
Sponsors
Division of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)CTEPH was diagnosed with V/Q scintigraphy and/or pulmonary angiography 2)Patients under warfarin 3)Stable patients after standard theraphy for CTEPH has been completed. 4)>= 20 years old 5)Patient with a written informed consent
Exclusion criteria
Exclusion criteria: 1)Patient who is scheduled for PEA and/or BPA. 2)Newly initiation of soluble guanylate cyclase stimulator 3)Recent induction of homeoxygen therapy 4)Contraindication for edoxaban 5)High risk patients of bleeding 6)Past history of alveolar hemorrhage 7)cCr<30mL/min 8)Patients who taking more than 2 antiplatelet drugs 9)pregnant/lactating woman
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical worsening events during six months after switching to edoxaban from warfarin on CTEPH | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of clinical parameters (Hemodynamics,right heart function, systemic vascular function, oxygenation, exercise capacity, quality of life, coagulation-lysis systems) at 6 months after edoxaban on CTEPH | — |
Countries
Japan
Contacts
Public ContactKazuhiko Nakayama
Department of Internal Medicine Division of Cardiovascular Medicine
Outcome results
None listed